Inhibitors of secretory phospholipase A2 (sPLA2), which generates LPA (unspecified species) precursors, have shown preclinical activity
In addition, GLP-1 inhibits glucagon release (which slows down the release of sugar into the blood so that you burn more fat), slows down gastric emptying (makes you feel full), and lowers the desire for food intake (because you feel full)
A year ago, the gap was narrower
Lifestyle factors play a significant role in the frequency and intensity of heart palpitations
Exenatide GLP-RA , 1995 2005 .60 Liraglutide 2010 2 ,62 lixisenatide 2013 2 , 2 016 7 .63 (Albiglutide) 2014 3 , 2014 4 .64 (Dulaglutide) 2014 9 T2DM ,65 (Semaglutide) 2017 9 .66 (Beinaglutide) GLP-RA , 2016 9 T2DM .67 PEG-(PEG-loxenatide) GLP-RA , 2019 5 .66 ( 1 2) Table 1 Comparison of GLP-1RAs used in type 2 diabetes mellitus DateBrand nameGLP-1RAHalf-lifeDose (SC)Molecular formulaClinial trial focus Table 2 Comparative overview of efficacy and adverse effects of mainstream GLP-1RA medications Current GLP-1RAs GLP-1RAs are synthetic protein preparations that have partial or complete amino acid sequence homology with GLP-1 found in the body, are not easily degraded, have longer half-lives and have stronger biological activity
Preventing Microbial Contamination Always use sterile techniques and solvents
